IP Library › Granted Patent US 9,511,140
Granted Patent B2
US 9,511,140 · App. 15/064,343 · Granted Dec 6, 2016

Stable VEGF antagonist formulations

Inventors: Daniel Dix (LaGrangeville, NY); Kelly Frye (Mendham, NJ); Susan Kautz (Albany, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A61K39/39591A61K9/0019A61K9/08A61K9/19A61K31/4172A61K31/7012A61K38/16A61K38/179A61K47/02A61K47/10A61K47/183A61K47/22A61K47/26C07K14/71C07K16/22C07K2318/20C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,511,140
App. No.
15/064,343
Granted
Dec 6, 2016
Kind
B2
Abstract

Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.

Claims (8)

1. A stable liquid formulation of a vascular endothelial growth factor (VEGF)-specific antagonist, comprising: 10-100 mg/ml of a fusion protein comprising a receptor component, which comprises an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor and an Ig domain 3 of a second VEGF receptor, and a multimerizing component; 1-10 mM phosphate buffer; 1-10 mM citrate buffer; 25-150 mM NaCl; and 5-30% sucrose, at a pH of about 6-6.5.

2. The stable liquid formulation of claim 1 , comprising: 10-50 mg/ml of the fusion protein, which comprises amino acids 27-457 of SEQ ID NO: 4; 5 mM phosphate buffer; 5 mM citrate buffer; about 20% sucrose; about 100 mM NaCl; and about 0.1% polysorbate 20, at a pH of about 6.2.

3. The stable liquid formulation of claim 2 , comprising about 25 mg/ml of the fusion protein.

4. The stable liquid formulation of claim 3 , wherein the VEGF-specific antagonist comprises a dimer of the fusion protein.

5. The stable liquid formulation of claim 4 , comprising: 25 mg/ml of the VEGF-specific antagonist; 5 mM phosphate buffer; 5 mM citrate buffer; 100 mM NaCl; 20% sucrose; and 0.1% polysorbate 20, at a pH of about 6.2.

6. The stable liquid formulation of claim 5 , wherein less than about 1% of the VEGF-specific antagonist is degraded after three years of storage at 2-8° C.

7. A stable liquid formulation of a VEGF-specific antagonist, comprising: about 25 mg/mL of a homodimer consisting essentially of amino acids 27-457 of SEQ ID NO: 4; about 5 mM phosphate buffer; about 5 mM citrate buffer; about 20% sucrose; about 100 mM NaCl; and about 0.1% polysorbate 20, at a pH of about 6.2.

8. The stable liquid formulation of claim 7 , wherein less than about 1% of the VEGF-specific antagonist is degraded after three years of storage at 2-8° C.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2016
From: DIX, DANIEL; FRYE, KELLY; KAUTZ, SUSAN
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 038181/0885 →
Continuity (8)
Continuation 14550385 · Nov 21, 2014
Continuation 13909745 · Jun 4, 2013
Continuation 13428510 · Mar 23, 2012
Continuation 13343214 · Jan 4, 2012
Division 12835065 · Jul 13, 2010
Continuation 11387256 · Mar 22, 2006
Provisional Application 60665125 · Mar 25, 2005
Related Publication 20160175439A1 · Jun 23, 2016